all prices
| price | high | low | % | ||
|---|---|---|---|---|---|
| Dow Jones | 27942 | 28016 | 27930 | -0.3 % | |
| S&P500 | 3140 | 3149 | 3140 | -0.18 % | |
| Nasdaq 100 | 8381 | 8426 | 8379 | -0.24 % | |
| Euro Stoxx 50 | 3669 | 3691 | 3668 | -0.69 % | |
| FTSE 100 | 7233 | 7256 | 7214 | 0 % | |
| CAC40 | 5832 | 5871 | 5831 | -0.81 % | |
| DAX | 13097 | 13181 | 13094 | -0.61 % | |
| Hong Kong HSI | 26421 | 26626 | 26409 | -0.49 % | |
| Nikkei 225 | 23389 | 23544 | 23366 | -0.66 % |
Live stock markets prices
- 15 min
- 1H
- 4H
- Daily
| Dow Jones | 27942 | -0.3% |
|---|---|---|
| S&P500 | 3140 | -0.18% |
| Nasdaq 100 | 8381 | -0.24% |
| FTSE 100 | 7233 | 0% |
| CAC40 | 5832 | -0.81% |
|---|---|---|
| Nikkei 225 | 23389 | -0.66% |
| Euro Stoxx 50 | 3669 | -0.69% |
| DAX | 13098 | -0.6% |
Latest news
| Konica Minolta Receives Keypoint Intelligence – Buyers Lab PaceSetter Award for Security |
| Gentex Announces 4th Quarter 2019 Cash Dividend |
| B.C. Honours Excellence in Nursing |
| WISeKey to Present at the Imperial Capital Security Investor Conference on December 11th in New York City |
| The Scottish Salmon Company PLC: Primary Insider Transaction |
| The Scottish Salmon Company PLC:Transfer of Treasury Shares |
| Final result of the rights issue in Oasmia |
| SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Fiat Chrysler Automobiles N.V. – FCAU |
| Directorate Change |
| vCom Solutions Releases vManager 12 to Expand Coverage of IT Spend Categories |
| North American Palladium Receives Final Order |
| DEINOVE and ESPCI Paris obtain funding from the ANR to develop the Deinodrop technology |
| PIH Health Announces Ramona Pratt and Ceonne Houston-Raasikh as Chief Nursing Officers of PIH Health |
| The M.S. in Applied Behavioral Analysis Program at The Chicago School of Professional Psychology Earns Accreditation |
| ProVen Growth and Income VCT plc: Director/PDMR Shareholding |
| LVMH: Share Transactions Disclosure |
| ASMI Share Buyback Update December 2 - 6, 2019 |
| Eramet: Purchase of own shares |
| EVS Broadcast Equipment reports update of share buyback program |
| BONDUELLE - Monthly statement of the number of shares and voting rights |
Konica Minolta Receives Keypoint Intelligence – Buyers Lab PaceSetter Award for Security
Security Services Portfolio from Companyâs IT Services Division, All Covered, Considered Top Notch
Ramsey, NJ, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta), is proud to announce it has received the prestigious Keypoint Intelligence â Buyers Lab PaceSetter award in Security: IT Assessment & Remediation for security services provided by its IT Services Division, All Covered. Konica Minoltaâs innovative solutions, Workplace Hub and Dispatcher Phoenix 6, were also honored by Keypoint Intelligence as announced last week.
Keypoint Intelligence conducted an in-depth evaluation of the security offerings of 10 document imaging OEMs. The granular study drilled down into more than 75 points of potential differentiation spread across key categories. The âIT Assessment & Remediationâ award honors the vendor that has the most complete IT security service abilities for both general business and key vertical markets.
âOur commitment to innovation in providing industry-leading solutions in IT security continues to be recognized and for that we are grateful,â said Todd Croteau, President, All Covered. âOur IT engineers work with our customers to provide customized security strategies and solutions that keep their businesses flourishing, and this honor from Keypoint Intelligence affirms that we are providing best-in-class service to our clients.â
Comments from Keypoint Intelligence on Konica Minoltaâs IT Services Division, All Covered: Konica Minolta led the pack in the area of security assessment and remediation, bolstered by the IT security services portfolio of its All Covered subsidiary. Spanning areas like email security, patching and endpoint protection, penetration testing and vulnerability assessments, 24/7 security services, cybersecurity and vulnerability management, and IT compliance (including HIPAA compliance), Konica Minolta goes well beyond the document infrastructure to ensure top-notch data security. Another notable aspect of its IT security program is the availability of a vCISO (virtual chief information security officer) as a managed service. And when it comes to sales strategy, these security services can be provided directly through Konica Minolta or in partnership with an independent office equipment dealerâwidening customer access to a hardened network infrastructure. Konica Minoltaâs strength in document security, in areas like data loss prevention and fingerprint reader authentication, as well as its investment in intelligence IP surveillance cameras and software, contribute to its overall standing as a security-focused technology company, too.
As part of its mission to help businesses achieve their goals through better management of information and more effective collaboration, All Covered provides ongoing security-focused educational opportunities for businesses to learn how to protect their systems and data. Register today for All Coveredâs webinar, âCountdown to Microsoft Server 2008 End of Support,â happening on January 15 and 16.
About Konica Minolta
Konica Minolta Business Solutions U.S.A., Inc. is reshaping and revolutionizing the Workplace of the Futureâ¢Â with its expansive smart office product portfolio from IT Services (All Covered), ECM, Managed Print Services and industrial and commercial print solutions. Konica Minolta has been recognized as the #1 Brand for Customer Loyalty in the MFP Office Copier Market by Brand Keys for twelve consecutive years, and is proud to be ranked on the Forbes 2017 America's Best Employers list. The World Technology Awards recently named the company a finalist in the IT Software category. Konica Minolta, Inc. has been named to the Dow Jones Sustainability World Index for eight consecutive years. It partners with its clients to give shape to ideas and work to bring value to our society. For more information, please visit us online and follow Konica Minolta on Facebook, YouTube, Linked In and Twitter.
About Keypoint Intelligence - Buyers Lab
Keypoint Intelligence is a one-stop shop for the digital imaging industry. With our unparalleled services and unmatched depth of knowledge, we cut through the noise of data to offer clients the independent insights and responsive tools they need in those mission-critical moments that define their products and empower their sales.
For over 50 years, Buyers Lab has been the global document imaging industryâs resource for unbiased and reliable information, test data, and competitive selling tools. What started out as a consumer-based publication about office equipment has become an all-encompassing industry resource. Buyers Lab evolves in tandem with the ever-changing landscape of document imaging solutions, constantly updating our methods, expanding our offerings, and tracking cutting-edge developments.
About Buyers Lab PaceSetter Awards
Based on exhaustive questionnaires, in-depth interviews, and a proprietary rating scale, Buyers Lab PaceSetter awards recognize those document imaging OEMs that have shown market leadership in a variety of categories, including with technologies, services, and key vertical markets.
#####
Gentex Announces 4th Quarter 2019 Cash Dividend
ZEELAND, Mich., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected car, dimmable glass, and fire protection technologies, today announced that its Board of Directors recently declared a quarterly cash dividend of $0.115 (11.5 cents) per share that will be payable January 22, 2020, to shareholders of record of the common stock at the close of business on January 8, 2020.
About the Company
Founded in 1974, Gentex Corporation (The NASDAQ Global Select Market: GNTX) is a supplier of automatic-dimming rearview mirrors and electronics to the automotive industry, dimmable aircraft windows for aviation markets, and fire protection products to the fire protection market. Visit the Companyâs websites at www.gentex.com and gentextech.com.
Contact Information
Gentex Investor Relations
616-772-1590 x5814
B.C. Honours Excellence in Nursing
VANCOUVER, British Columbia, Dec. 09, 2019 (GLOBE NEWSWIRE) -- The Association of Nurses and Nurse Practitioners of BC (NNPBC), the only professional association in the province representing all four nursing designations, is proud to honour 18 exceptional individuals who have demonstrated excellence in nursing practice including ârising starsâ in the profession, lifetime achievement, research, advocacy, innovation, education and leadership at the 2019 Nursing Awards of Excellence.
âRecognizing the great work nurses have done is a high priority for NNPBC. Nurses are the backbone of our healthcare system. While we honour and value the work nurses do each day, we are thrilled to have the opportunity to acknowledge 18 exceptional nurses who have demonstrated the best of the profession over the past year,â said Jacqollyne Keath, NNPBC Board Chair.
This is NNPBCâs second nursing awards of excellence ceremony and continues to be a unique opportunity to showcase unity in the profession by ensuring that all four nursing designations in British Columbia (Licensed Practical Nurse, Nurse Practitioner, Registered Nurse and Registered Psychiatric Nurse), are recognized for their contributions to nursing and healthcare.
âThe Nursing Awards of Excellence demonstrate the strength of the profession by showcasing nursesâ exemplary work across all designations, domains of practice and sectors. What a wonderful way for NNPBC to promote unity and collaboration in our profession by hosting these fantastic nurses, their families, friends and colleagues in celebration of all that nursing brings to the table,â said Michael Sandler, NNPBC Executive Director.
Nursing Excellence Award winners for 2019 include:
- Kathleen Fyvie, NP â Lifetime Achievement
- Morrie Steele, RN (retired), RPN (retired) â Lifetime Achievement
- Paisly Symenuk, RN â Excellence in Nursing Advocacy
- Lisa Bourque Bearskin, RN â Excellence in Advancing Nursing Knowledge & Research
- Emily Jenkins, RN â Excellence in Advancing Nursing Knowledge & Research
- Nelly Oelke, RN â Excellence in Advancing Nursing Knowledge & Research
- Sheila Epp, RN â Excellence in Nursing Education
- Ranjit K. Dhari, RN â Excellence in Nursing Education
- Sarah Foster, LPN- Excellence in Nursing Leadership
- Brent Hobbs, RN â Excellence in Nursing Leadership
- Minna Miller, NP â Excellence in Nursing Leadership
- Carrie Murphy, NP â Excellence in Nursing Leadership
- Sian Bethan Roberts, RN â Excellence in Nursing Practice
- Angela Russolillo, RPN â Excellence in Nursing Practice
- Barbara Pesut, RN â Innovation in Nursing
- Lauren Colby, NP â Rising Star
- Fin Gareau, NP- Rising Star
- Rachel Kathleen Walker, RPN â Rising Star
NNPBC represents all four of B.C.âs nursing designations and serves as the voice for professional practice, advocacy and leadership, and is the jurisdictional representative to the Canadian Nurses Association.
Contact:
Michael Sandler, Executive Director
604.209.1149
info@nnpbc.com
WISeKey to Present at the Imperial Capital Security Investor Conference on December 11th in New York City
WISeKey to Present at the Imperial Capital Security Investor Conference on December 11th in New York City
ZUG, Switzerland â December 9, 2019 â WISeKey International Holding Ltd (âWISeKeyâ, NASDAQ: WKEY, SIX: WIHN), a leading cybersecurity and IoT company, today announced that Carlos Moreira, Founder and CEO will present at the Imperial Capital Security Investor Conference, on December 11, 2019, at 4:15 pm ET, at the Intercontinental New York Barclay.
The presentation will not be webcast; however, investors will be able to download the most recent investor presentation via the Investors section of WISeKeyâs website, www.wisekey.com. Â Additionally, Mr. Moreira will host one-on-one meetings with investors throughout the day.
About WISeKey
WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey Microprocessors Secures the pervasive computing shaping todayâs Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.). WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens.
Our technology is Trusted by the OISTE/WISeKeyâs Swiss based cryptographic Root of Trust (âRoTâ) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit www.wisekey.com.
Press contacts:
| WISeKey International Holding Ltd Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com | WISeKey Investor Relations (US) Contact: Lena Cati The Equity Group Inc. Tel: +1 212 836-9611 lcati@equityny.com |
Disclaimer:
This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.
The Scottish Salmon Company PLC: Primary Insider Transaction
Reference is made to the Company's announcement dated 9th December regarding the transfer of treasury shares under the Company's Share Incentive Plan ("SIP"). As a participant in the SIP James Billett, a primary insider, has purchased 127 shares of the Company at the average market price of NOK 28.25 per share. Â Subsequently to this purchase Mr Billett owns 173 shares in The Scottish Salmon Company PLC.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
The Scottish Salmon Company PLC:Transfer of Treasury Shares
The Scottish Salmon Company PLC has accepted the mandatory offer from Bakkafrost for 138,675 Treasury Shares. The Scottish Salmon Company PLC ('the Company') has also sold 13,982 Treasury Shares to employees as part of the Company's 2019 Share Incentive Plan (âSIPâ), the shares were sold at NOK 28.25 per share being the closing share price on 6th December 2019. Following the acceptance of the mandatory offer and the SIP transfers the Company holds 1,108 treasury shares. The Scottish Salmon Company PLC share capital remains unchanged at NOK 174,626,256 divided into 194,029,173 fully paid common shares, each with a par value of NOK 0.90.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Final result of the rights issue in Oasmia
The final result of the rights issue in Oasmia Pharmaceutical AB (publ) (âOasmiaâ or the âCompanyâ) amounts to 198,329,980 shares subscribed for with subscription rights, which corresponds to approximately 99.5 percent of the rights issue. The remaining 945,372 shares have been allotted without subscription rights, which corresponds to approximately 0.5 percent of the offered shares. Â Thus, the rights issue is fully subscribed and Oasmia receives proceeds amounting to approximately SEK 399 million before costs related to the rights issue.
The final result of the rights issue in Oasmia, in which the subscription period took place from and including 20 November 2019 up to and including 4 December 2019, amounts to 198,329,980 shares subscribed for in the rights issue with subscription rights, which corresponds to approximately 99.5 percent of the rights issue. Through the previously announced subscription commitment, Per Arwidsson via Arwidsro Investment AB has subscribed for 22,500,000 of these shares through set-off in the rights issue. In addition, the Company has received applications to subscribe for 78,446,921 shares without subscription rights, corresponding to approximately 39.4 percent of the rights issue. Accordingly, in total 276,776,901 shares have been subscribed or registered for subscription in the rights issue, which corresponds to approximately 138.9 percent of the rights issue. Thus, the rights issue is fully subscribed and Oasmia receives proceeds amounting to approximately SEK 399 million before deduction of costs related to the rights issue. Through the rights issue, Oasmiaâs share capital will increase by SEK 19,927,535.2 from SEK 24,909,419.4 to SEK 44,836,954.6 by issuing 199,275,352 new shares. The total number of shares will amount to 448,369,546 shares after the rights issue has been registered.
Allotment of the remaining 945,372 shares, which have been subscribed for without subscription rights, have been carried out in accordance with the principles in the prospectus published by Oasmia on 19 November 2019. As confirmation of allotment of shares subscribed for without subscription rights, a contract note will be sent on or about 10Â December 2019. Subscribed and allotted shares must be paid for in cash in accordance with the instructions in the contract note. Nominee-registered shareholders will receive notice of allotment in accordance with the procedures of the nominee. Only those who have been allotted shares will be notified.
The final day for trading in paid subscribed shares (BTA) will be on 16 December 2019. The new shares are expected to start trading on Nasdaq Stockholm on or about 18Â December 2019.
Advisors
ABG Sundal Collier is the financial advisor to Oasmia and Hannes Snellman is the legal advisor to Oasmia in connection with the rights issue. Baker McKenzie is the legal advisor to ABG Sundal Collier in connection with the rights issue.
For more information:
Urban Ekelund, IR Manager Oasmia
Telephone: +46(0)18-50 54 40
E-mail:Â IR@oasmia.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology. The companyâs product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The companyâs product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM) and Frankfurt Stock Exchange (OMAX.GR).
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions and the recipients of this press release in jurisdictions in which this press release has been released, announced or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Oasmia in any jurisdiction either from Oasmia or from someone else.
Any investment decision in connection with the rights Issue must be made on the basis of all publicly available information relating to the Company and the Companyâs shares. Such information has not been independently verified by ABG Sundal Collier. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the âSecurities Actâ), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into, to the United States, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
This press release is not a prospectus for the purposes of the (EU) Regulation 2017/1129 (the âProspectus Regulationâ) and has not been approved by any national competent authority in any jurisdiction. A prospectus in relation to the rights Issue as described in this press release has been prepared by the Company and the prospectus has been scrutinized and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and has been published on, inter alia, Oasmiaâs web page.
In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, âqualified investorsâ who are (i) persons having professional experience in matters relating to investments who fall within the definition of âinvestment professionalsâ in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the âOrderâ); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ârelevant personsâ). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
Forward-looking statements
This press release contains forward-looking statements that reflect the Companyâs intentions, beliefs, or current expectations about and targets for the Companyâs future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates, including with respect to prospects for pharmaceutical treatments and studies. Forward-looking statements are statements that are not historical facts and may be identified by words such as âbelieveâ, âexpectâ, âanticipateâ, âintendâ, âmayâ, âplanâ, âestimateâ, âwillâ, âshouldâ, âcouldâ, âaimâ or âmightâ, or, in each case, their negative, or similar expressions. The forwardlooking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required according to any law or Nasdaq Stockholmâs rulebook for issuers.
Information to distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (âMiFID IIâ); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the âMiFID II Product Governance Requirementsâ), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any âmanufacturerâ (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Offered shares have been subject to a product approval process, which has determined that the Offered shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the âTarget Market Assessmentâ). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Offered shares may decline and investors could lose all or part of their investment; the Offered shares offer no guaranteed income and no capital protection; and an investment in the Offered shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the rights Issue. Furthermore, it is noted that, notwithstanding the Target Market Assessment, ABG Sundal Collier will only procure investors who meet the criteria of professional clients and eligible counterparties.
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to Oasmiaâs shares.
Each distributor is responsible for undertaking its own target market assessment in respect of Oasmiaâs shares and determining appropriate distribution channels.
Attachment
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Fiat Chrysler Automobiles N.V. – FCAU
NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fiat Chrysler Automobiles N.V. (NYSE: FCAU) from February 26, 2016 through November 20, 2019 inclusive (the âClass Periodâ). The lawsuit seeks to recover damages for Fiat Chrysler Automobiles N.V. investors under the federal securities laws.
To join the class action, go http://pawarlawgroup.com/cases/fiat-chrysler-automobiles-n-v/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Fiat employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with International Union, United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat official were aware of and authorized the scheme; and (3) due to the foregoing, defendantsâ statements about Fiatâs receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 31, 2020. Â A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.Â
Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Vik Pawar, Esq. Â
Pawar Law Group Â
20 Vesey Street, Suite 1410Â Â
New York, NY 10007Â Â
Tel: (917) 261-2277Â Â
Fax: (212) 571-0938Â Â
info@pawarlawgroup.com Â
Directorate Change
Seneca Growth Capital VCT Plc (the âCompanyâ)
9 December 2019
Appointment of Director
As envisaged in the Companyâs Annual Report, which was published in April 2019, the Company has carried out a search for a further Non-Executive Director and is pleased to announce the appointment of Alex Clarkson to the Board and to the Audit Committee with effect from 9 December 2019.
Alex is a Managing Director of Bamburgh Capital. He qualified as a chartered accountant with PricewaterhouseCoopers in 1998, joined Brewin Dolphin Securities in 2000 before becoming co-founder of Zeus Capital in 2003. Alex then went on to co-found Bamburgh Capital in 2011, executing over 20 transactions acting on both the âbuyâ and âsellâ side and raising funding. During this time, Alex was co-founder of Compass BioScience Group Limited and Collbio, two highly acquisitive companies, and became interim CFO of Collbio which undertook an IPO on the London Stock Market within an 18-month period, changing its name to Collagen Solutions.
Alex will stand for re-election by shareholders at the Annual General Meeting of the Company to be held in 2020. Â In relation to this appointment, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.
The Board now consists of four Directors comprising two Independent Directors who were appointed prior to the appointment of Seneca Partners Limited (âthe Managerâ), Richard Manley, who is the representative of the Manager and Alex Clarkson, who is the third Independent Director. Notwithstanding that the Company is listed, it is one of the smallest by market value at present and is, therefore, not strictly subject to the recommendations of the Hampton-Alexander Report in respect of diversity. However, the Board fully supports the aims of that Report and intends to make further appointments to the Board in due course and will, over time, strive to comply with these recommendations.
For further information, please contact:
John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com
Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk
vCom Solutions Releases vManager 12 to Expand Coverage of IT Spend Categories
Major enhancements increase self service capabilities
SAN RAMON, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- vCom Solutions, a leader in IT lifecycle and spend management software and services, today announced the latest release of vManager, the companyâs proprietary software platform. Major enhancements within vManager 12 focus on expanding corporate visibility into the key areas of IT spend â Networks, Mobility, Collaboration, Cloud, Hardware and SaaS â and improving self-service capabilities across the platform.
vManager 12 improves the platform user experience through the addition of self-service tools and enhancements that increase the speed at which users can access, manage and purchase IT assets. Customization tools allow for flexible delivery of data based on client needs. More importantly, the improved platform organization simplifies the complexity of managing assets across six different categories of spend. Â Â
âvManagerâs capabilities have grown alongside the demands of our clients,â said Srihari Hosahalli, vCom Chief Information Officer. âSmall and mid-sized businesses have the same IT infrastructure struggles as large enterprises, only with a fraction of the resources. So, the need for one essential tool to provide access to every facet of that IT spend â whether itâs managing cloud instances or making sense of SaaS licenses â is paramount.â
âAnything that allows us to gain more clarity into our IT environment and better control how and where our IT budget is spent is a value-add to us,â said Marvin Woods, director, Network Operations for GardaWorld, the largest privately owned security services company in the world. âvManager 12 will provide us the ability to sort through all of our spend assets by category and that will be a tremendous timesaver, especially when it comes to managing things like trouble tickets. Weâll be able to see exactly how many mobile issues weâre dealing with, without having to sort through every other kind of ticket. Additionally, the flexibility of the self-service enhancements will make it easier for my team to control how they get price quotes or roll out new assets, depending on whatâs more efficient. Overall, the fact that vCom continually makes enhancements to vManager based on feedback from clients is one of the reasons weâve been a customer since 2001.â
vManager 12 new capabilities and enhancements include:
- Spend Category Tabs â Each of the six categories of IT spend â Networks, Mobility, Collaboration, Cloud, Hardware, and SaaS â has been separated into its own tab on the vManager 12 platform. Users no longer have to sort through a collective inventory to isolate the assets, tickets, licensing, etc. of any one spend type. With one click on the appropriate spend category tab, users can access everything within that category and quickly locate specific assets. This streamlines customer experience and improves ease-of-use and efficiency.
- Mobile Shop/Buy â The platformâs Shop/Buy online pricing capabilities now include mobile services. Users can shop for mobile phones, routers, accessories, etc. live and obtain near-immediate price quotes from various providers or can request quotes through vComâs Technology Solutions Group.
- AP Configuration Wizard â vManager 12 allows users to build and customize their cost allocation and AP posting files. Previously requiring backend help from vCom experts, users can now generate their own AP posting files and allocate based on inventory, location, cost center, etc.
- Pending Inventory Tool â Provides the ability for users to enter assets into vManager 12 from carrier invoices. Clients are now able to choose which assets from carrier invoices are managed within vManager. Streamlines the asset loading process and empowers users to manage it themselves.
- Catalog Management â Organizations can build mobile and hardware catalogs within vManager 12, customizing selection options based on pre-defined criteria.
About vCom Solutions
vCom is a cloud-based software and managed services company focused on helping enterprises manage IT spend from procure-to-pay. vCom improves visibility and control within a single software while decreasing expenses for networks, mobile, cloud, collaboration, hardware and SaaS technologies. To learn more about vCom visit http://vcomsolutions.com.
Media Contact:
Renee Maler
Philosophy PR + Marketing
For vCom Solutions
5104999746
renee@philosophypr.comÂ
Photos accompanying this announcement are available at:Â
https://www.globenewswire.com/NewsRoom/AttachmentNg/93cad0e8-2852-463b-adba-310c75c1cd52
https://www.globenewswire.com/NewsRoom/AttachmentNg/10569a9a-3f28-4f02-b3db-869e73dae133
North American Palladium Receives Final Order
TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- North American Palladium Ltd. ("NAP" or the "Company") (TSX:PDL) (OTC PINK:PALDF) today announced that all of the required regulatory approvals have been obtained with respect to the proposed plan of arrangement (the âArrangementâ) pursuant to which an affiliate of Impala Platinum Holdings Limited (the "Purchaser") will acquire all of the issued and outstanding common shares of the Company (the "Shares") by way of a plan of arrangement. Under the terms of the Arrangement, shareholders of NAP other than Brookfield (defined below), will receive C$19.74 per Share in cash and Brookfield Business Partners L.P. (together with its institutional partners, collectively âBrookfieldâ), as the majority shareholder of NAP, will receive C$16.00 per Share in cash.
The parties currently anticipate that the transaction will close on or about December 13, 2019.
Shareholders who have questions or require assistance with submitting their Shares to the Arrangement may direct their questions to Computershare Trust Company of Canada, who is acting as depositary under the Arrangement, toll free at 1-800-564-6253 or by email at corporateactions@computershare.com. Further information regarding the Arrangement is available in the management information circular of the Company dated November 1, 2019, which is available under NAP's profile on SEDAR at www.sedar.com.
About North American Palladium Ltd.
North American Palladium (TSX: PDL) (OTC PINK: PALDF) is a Canadian company with 25 years of production at the Lac des Iles Mine in a low-risk jurisdiction northwest of Thunder Bay, Ontario. North American Palladium is the worldâs only pure play palladium producer. With over 675 employees, the Lac des Iles Mine features a unique, world-class ore body and modern infrastructure, including both an underground mine and surface operations.
For further information, please contact:
North American Palladium Investor Relations at ir@nap.com.
DEINOVE and ESPCI Paris obtain funding from the ANR to develop the Deinodrop technology
DEINOVE et lâESPCI Paris obtiennent un financement de lâANR
pour développer la technologie Deinodrop
Â
- La technologie Deinodrop sera codéveloppée par lâESPCI et DEINOVE pour accélérer la découverte et l'identification de bactéries productrices de nouveaux antibiotiques.
- Lâobjectif : développer une technologie de criblage et de tri à très haut débit de bactéries en gouttelettes.
- Lâavantage : faciliter la détection dâactivités antibiotiques et permettre un criblage sur cellules uniques donnant accès à des espèces réputées non-cultivables.
- LâANR a accordé à Deinodrop un financement de 300kâ¬, à la suite dâun processus de sélection très exigeant.
DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française qui sâappuie sur une démarche dâinnovation radicale pour développer des antibiotiques innovants et des ingrédients actifs biosourcés pour la cosmétique et la nutrition, annonce avoir obtenu, conjointement avec lâESPCI Paris1, un financement de 300k⬠de lâANR2 pour le co-développement dâun système innovant dâisolement, de culture et de criblage de bactéries.
Le projet de recherche partenarial Deinodrop, associant DEINOVE et lâESPCI Paris, a été retenu par lâANR dans le cadre de lâappel à projets PRCE « Technologies pour la santé ». Dâune durée de deux ans, il est doté dâun financement de 300kâ¬.
Ce projet, qui vient en support du programme AGIR, vise à développer un système innovant de tri en microfluidique en gouttes de bactéries environnementales dans lequel chaque gouttelette constitue un microréacteur. Une fois mise au point, cette technologie offrira de nombreux avantages pour accélérer les travaux de recherche et augmenter le taux de réussite du programme AGIR :
- Sensibilité accrue du criblage, pour une meilleure détection des antibiotiques dâintérêt ;
- Augmentation du débit de criblage et de tri des bactéries, jusquâà 800 gouttes par seconde, tout en optimisant la quantité de réactifs utilisée ;
- Capacité de détection, de tri et d'analyse des bactéries réputées non-cultivables dans les conditions de laboratoire classiques.
 « Nous sommes fiers que le projet DEINODROP ait été retenu par lâANR. Seuls 15% des projets soumis sont retenus, cela vient donc saluer la qualité de notre technologie, », déclare Raphaël CALBRIX, Responsable de la plateforme Banking et Robotique de DEINOVE. « Notre objectif est de développer une technologie de rupture dans la culture et la sélection de bactéries afin de pouvoir analyser des quantités considérables de microorganismes et découvrir de nouvelles activités antibiotiques susceptibles de répondre à lâenjeu majeur de lâantibiorésistance. »
à PROPOS DU PROGRAMME AGIR
Le programme AGIR â Antibiotiques contre les Germes Infectieux Résistants â a été retenu en 2017 par le Programme dâInvestissements dâAvenir et bénéficie dâun soutien financier de Bpifrance de 14,6 m⬠sur 5 ans.
Une plateforme dédiée à lâidentification de structures antibiotiques inédites à partir de souches bactériennes rares
Le PSPC (Projets de recherche et développement Structurants Pour la Compétitivité) AGIR vise lâexploration systématique de la biodiversité, principalement des micro-organismes rares, afin dâidentifier et de développer un portefeuille de candidats-médicaments.
Alors que le monde manque de nouveaux antibiotiques, la recherche se concentre toujours majoritairement sur un petit nombre de micro-organismes dâintérêt, ou sur la construction par synthèse chimique de molécules dérivées de médicaments existants.
A lâinverse, le programme AGIR développe de nouvelles méthodes de collecte, de culture et dâévaluation du potentiel antibiotique de souches bactériennes rares, ainsi que dâoptimisation de molécules.
Le programme AGIR est conduit avec l'Institut Charles Viollette (Université de Lille) qui apporte ses compétences en matière de génie microbien et enzymatique et de caractérisation des molécules produites.
Un projet collaboratif ambitieux renforcé par des partenariats stratégiques ciblés visant à élargir le champ des recherches
Capitalisant sur sa technologie qui lui permet dâautomatiser et dâaccélérer lâanalyse fine de grandes quantités de souches, DEINOVE vise à maximiser les opportunités de découvrir de nouvelles structures antibiotiques en élargissant son champ de recherche au-delà de sa propre bibliothèque bactérienne.
DEINOVE a noué des partenariats avec plusieurs sociétés détenant des souches diverses collectées dans le cadre de leurs activités pharmaceutiques, notamment bioMérieux et Naicons.Â
Â
à PROPOS DE DEINOVE
DEINOVE est une société de biotechnologie française, leader de lâinnovation radicale, qui entend contribuer à relever les défis que représentent la résistance aux antibiotiques et la transition vers un modèle de production durable pour les industries de la nutrition et de la cosmétique.
DEINOVE a développé une expertise unique et exhaustive dans le domaine des bactéries rares quâelle sait décrypter, cultiver, optimiser pour en révéler les possibilités insoupçonnées et ainsi leur faire produire à lâéchelle industrielle des molécules biosourcées aux activités dâintérêt. A cette fin, DEINOVE constitue et documente depuis sa création une réserve inégalée de diversité biologique quâelle exploite grâce à une plateforme technologique unique en Europe.
DEINOVE se développe dans deux domaines d'activité :
- ANTIBIOTIQUES, anti-infectieux de nouvelle génération : un premier candidat-antibiotique est désormais en Phase II. La Société poursuit également lâexploration systématique de la biodiversité pour alimenter son portefeuille en nouveaux leads, sâappuyant notamment sur des partenariats avec bioMérieux et Naicons (Programme AGIR soutenu par Bpifrance).
- BIOACTIFS, ingrédients actifs dâorigine naturelle avec la cosmétique comme premier marché et des potentiels en nutrition et en santé : DEINOVE commercialise déjà un premier actif innovant, un second en partenariat avec Greentech et prévoit de lancer de nouveaux actifs propriétaires en 2020. Plusieurs autres actifs cosmétiques sont en développement, notamment avec Oléos (Hallstar Group) et Dow. Un programme en nutrition animale avec le Groupe Avril est aussi en cours.
Au sein du parc dâactivités Euromédecine situé à Montpellier, DEINOVE emploie 60 collaborateurs, essentiellement des chercheurs, ingénieurs et techniciens, et a déposé plus de 350 demandes de brevets à lâinternational. La société est cotée sur EURONEXT GROWTH® depuis avril 2010.
CONTACTS
| Contacts investisseurs Coralie Martin Marketing, Communication et Relations investisseurs Tél : +33 (0)4 48 19 01 60 coralie.martin@deinove.com  Contacts Presse ALIZE RP Caroline Carmagnol Tél : +33 (0)6 64 18 99 59 deinove@alizerp.com | |
Â
1 LâÃcole supérieure de physique et de chimie industrielles de la ville de Paris
2 Agence Nationale de la Recherche
Â
Â
Attachment
PIH Health Announces Ramona Pratt and Ceonne Houston-Raasikh as Chief Nursing Officers of PIH Health
Ramona Pratt Named CNO of PIH Health Hospital - Whittier, Ceonne Houston-Raasikh as CNO of PIH Health Hospital - Downey
Whittier Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ramona Pratt, MSN, MSHCA, RN, and Ceonne Houston-Raasikh, DNP, MSN, RN, have been named PIH Health Hospital - Whittier and PIH Health Hospital - Downey chief nursing officers (CNO). Pratt will be responsible for executive oversight of PIH Health Hospital - Whittier nursing practice and operations and Houston-Raasikh will be responsible for executive oversight of PIH Health Hospital - Downey nursing practice and operations.
Pratt has worked for PIH Health for nearly 40 years, and has served the organization in executive roles since 2007. Most recently, she held the position of vice president of Oncology Services. Prior to that, she served as chief operating officer and chief nursing officer of PIH Health Hospital - Downey. Other executive positions she has held include, chief operating officer of PIH Health Physicians and vice president of Nursing Operations at PIH Health Hospital - Whittier. She became CNO in November 2019.
âIn my many years with PIH Health, I have been given the opportunity to grow within the organization and work in several different roles,â says Pratt. âNow I will be working with front line staff and nursing leadership to ensure we continue to provide outstanding care as we expand our presence in Southern California.â
Pratt is a registered nurse and has a Master of Science in Nursing and Healthcare Administration, and a Bachelor of Science in Nursing from California State University, Long Beach.
Houston-Raasikh became CNO in August 2019, and previously served as vice president of Nursing Operations for the PIH Health Hospital - Downey campus since March 2018. She joined PIH Health Hospital - Downey in 2017 as clinical director of Outpatient Surgical Center, Post-Anesthesia Care Unit, and Gastroenterology Services, and quickly advanced to administrative director of Surgical Services.
âIt is a pleasure to contribute to an organization that stands true to its vision of putting patients first,â says Houston-Raasikh. âIn my role as chief nursing officer, I will ensure that our team of caregivers maintains a high level of care for every patient that walks through our hospital doors.â
Dr. Houston-Raasikh is a registered nurse and holds a Doctorate in Nursing Practice from the University of San Francisco, a Master of Science in Nursing Administration and a Bachelor of Science in Nursing from California State University, Los Angeles.
###
About PIH Health
PIH Health is a nonprofit, regional healthcare network that serves approximately 2.5 million residents in the Los Angeles County, Orange County and San Gabriel Valley region. The fully integrated network is comprised of PIH Health Hospital - Whittier and PIH Health Hospital - Downey and features 27 outpatient medical locations, a multispecialty medical (physician) group, home healthcare services and hospice care, as well as heart, cancer, womenâs health, urgent care and emergency services. The organization is recognized by Watson Health as one of the nationâs Top Hospitals, and College of Healthcare Information Management Executives (CHIME) as one of the nationâs top hospital systems for best practices, cutting-edge advancements, quality of care and healthcare technology for both PIH Health Hospital - Whittier and PIH Health Hospital - Downey. Healthgrades®, the leading online resource for information about physicians and hospitals, recently honored PIH Health Hospital - Whittier with the 2019 Americaâs 250 Best Hospitals Award and for the fifth consecutive year, the Outstanding Patient Experience Award (2015-2019). PIH Health invests millions each year in community education and free and low-cost services to support those with the greatest need. PIH Health is also certified as a Great Place to WorkTM. For more information, visit PIHHealth.org or follow us on Facebook, Twitter, or Instagram.
Â
Attachments
The M.S. in Applied Behavioral Analysis Program at The Chicago School of Professional Psychology Earns Accreditation
The Association for Behavior Analysis International Accreditation Board grants Chicago program five years of accreditation
Chicago, Dec. 09, 2019 (GLOBE NEWSWIRE) -- After undergoing a rigorous review process and meeting the Association for Behavior Analysis International (ABAI) Accreditation Boardâs standards, the M.S. in Applied Behavioral Analysis Program at the Chicago Campus of The Chicago School of Professional Psychology has been granted full accreditation through December 31, 2024.
The Association for Behavior Analysis International Accreditation Board operates as a board of the ABAI and is the governance body responsible for the accreditation of training programs in behavior analysis at the bachelorâs, masterâs, and doctoral levels. Its mission is to establish and implement standards for the accreditation of educational programs in behavior analysis.
âWe are so proud to have reached this milestone,â said Department Chair Dr. Ashley Whittington-Barnish. âABAI accreditation is confirmation of the commitment our faculty and staff have to the success of our students. It speaks to the comprehensiveness, rigor, and quality of our program, one which offers students real-world training and all the competencies necessary to be successful scientists and practitioners. Our graduates are prepared to provide behavior analytic services in a wide range of settings, including clinics, homes, hospitals, and schools.â
âCongratulations to Dr. Whittington-Barnish and the ABA Department on this wonderful accomplishment,â said Chicago Campus Dean Margie Martyn, Ph.D. âThey have done amazing work to make the program successful, and this accreditation is recognition of their hard work and dedication.â
About The Chicago School of Professional Psychology
Founded in 1979, The Chicago School of Professional Psychology (TCSPP) is a nonprofit, private university devoted exclusively to psychology, and related behavioral health sciences. The institution serves almost 6,000 students across campuses in Chicago; Southern California (Los Angeles, Irvine and San Diego); Washington, D.C.; New Orleans; and Dallas, as well as through online programs. The Chicago School is accredited by the WASC Senior College and University Commission (WSCUC), and its Clinical Psychology Doctoral Programs in Chicago, Washington, D.C. and Los Angeles are accredited by the American Psychological Association. With more than 25 graduate degree programs, thousands of hours of real-world training, and a wealth of international opportunities, TCSPP is a leader in professional psychology and behavioral health education. To learn more, visit www.thechicagoschool.edu.
Â
The Chicago School is a proud affiliate of TCS, a nonprofit system of colleges advancing student success and community impact.
ProVen Growth and Income VCT plc: Director/PDMR Shareholding
ProVen Growth and Income VCT plcÂ
Director/PDMR Shareholding
9 December 2019
ProVen Growth and Income VCT plc (the âCompanyâ) hereby announces that on 6 December 2019, certain directors, and their closely associated persons, purchased ordinary shares of 1.6187 pence each in the Company. This notification relates to transactions notified in accordance with the Market Abuse Regulation, further details of which are set out below.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Malcolm Kennedy Hunt Moss
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ProVen Growth & Income VCT plc
b)
LEI
213800K1RM776QM8XG84
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of  1.6187 pence each
  Â
GB00B5B7YS03
b)
Nature of the transaction
Issue of shares pursuant to the Companyâs dividend reinvestment scheme.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
|  £0.617 | 2,288 |
 Â
d)
Aggregated information
| Â Aggregate Price | Aggregate Volume | Aggregate Total |
|  £0.617 |  2,288 |  £1,411.70 |
e)
Date of the transaction
6 December 2019
f)
Place of the transaction
London
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Natasha Isobel Christie-Miller
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ProVen Growth & Income VCT plc
b)
LEI
213800K1RM776QM8XG84
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of  1.6187 pence each
  Â
GB00B5B7YS03
b)
Nature of the transaction
Issue of shares pursuant to the Companyâs dividend reinvestment scheme.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
|  £0.617 | 1,007 |
 Â
d)
Aggregated information
| Â Aggregate Price | Aggregate Volume | Aggregate Total |
|  £0.617 |  1,007 |  £621.32 |
e)
Date of the transaction
6 December 2019
f)
Place of the transaction
London
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Roderick Wallace Christie-Miller
2
Reason for the notification
a)
Position/status
Spouse of Natasha Isobel Christie-Miller, Non-Executive Director
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ProVen Growth & Income VCT plc
b)
LEI
213800K1RM776QM8XG84
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of  1.6187 pence each
  Â
GB00B5B7YS03
b)
Nature of the transaction
Purchase under Offer for Subscription
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
|  £0.617 | 545 |
 Â
d)
Aggregated information
| Â Aggregate Price | Aggregate Volume | Aggregate Total |
|  £0.617 |  545 |  £336.27 |
e)
Date of the transaction
6 December 2019
f)
Place of the transaction
London
Beringea LLP
Company Secretary
Telephone 020 7845 7820
-End-
LVMH: Share Transactions Disclosure
Paris, December 2nd 2019
The disclosure of share transactions carried out on December 2nd, 2019 was sent to the AMF on December 9th, 2019. As required by current law, this document is publically available and can be consulted on the Companyâs website (www.lvmh.com) under the section «regulated information».
Attachment
ASMI Share Buyback Update December 2 - 6, 2019
Almere, The Netherlands
December 9, 2019, 5:45 p.m. CET
ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASMI's current share buyback program.
| Date | Repurchased shares | Average price | Repurchased value |
| December 2, 2019 | 30,000 | ⬠101.73 | ⬠3,051,832 |
| December 3, 2019 | 40,000 | ⬠100.18 | ⬠4,007,236 |
| December 4, 2019 | 25,000 | ⬠101.14 | ⬠2,528,593 |
| December 5, 2019 | 20,000 | ⬠101.53 | ⬠2,030,541 |
| December 6, 2019 | 30,000 | ⬠102.09 | ⬠3,062,562 |
| Total | 145,000 | ⬠101.25 | ⬠14,680,764 |
These repurchases were made as part of the â¬100 million share buyback program announced on November 1, 2019. Of the total program, 79.3% has been repurchased. For further details including individual transaction information please visit:
www.asm.com/investors/share-information/share-buyback.
About ASM International
ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
 Â
CONTACT
Investor contact:
Victor Bareño
T: +31 88 100 8500
E: victor.bareno@asm.com
Media contact:
Ian Bickerton
T: +31 625 018 512
Eramet: Purchase of own shares
Paris, December 9th 2019, 5:45 pm
PRESS RELEASE
Eramet: Purchase of own shares
Eramet announces the purchase of 10,000 of its own shares in order to cover for the free allocation of shares to employees and corporate officer.
§ Aggregated presentation per day and per market
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares* | |
| ERAMET | 549300LUH78PG2MP6N64 | 02/12/2019 | FR0000131757 | 2,000 | 41.14 | |
| ERAMET | 549300LUH78PG2MP6N64 | 03/12/2019 | FR0000131757 | 2,000 | 39.86 | |
| ERAMET | 549300LUH78PG2MP6N64 | 04/12/2019 | FR0000131757 | 2,000 | 40.49 | |
| ERAMET | 549300LUH78PG2MP6N64 | 05/12/2019 | FR0000131757 | 2,000 | 40.35 | |
| ERAMET | 549300LUH78PG2MP6N64 | 06/12/2019 | FR0000131757 | 2,000 | 40.02 | |
| *2 digit rounding after the decimal | Â | Â | TOTAL | 10,000 | 40.37 | |
§ Details per transaction
Detailed information regarding purchase of own shares (week of December 2nd 2019) is available on Eramet website: https://www.eramet.com/en/investors/publications-and-press-releases
Calendar
19.02.2020: Publication of 2019 annual results
20.02.2020: Webcast and presentation of 2019 annual results
28.04.2020: Publication of 2020 first quarter sales
ABOUT ERAMET
Eramet, a global mining and metallurgical group, is a key player in the extraction and valorisation of metals (manganese, nickel, mineral sands) and the elaboration and transformation of alloys with a high added value (high-speed steels, high-performance steels, superalloys, aluminium and titanium alloys).
The Group supports the energy transition by developing activities with high growth potential. These include lithium extraction and refining, and recycling.
Eramet positions itself as the privileged partner of its customers in sectors that include carbon and stainless steel, aerospace, pigments, energy, and new battery generations.
Building on its operating excellence, the quality of its investments and the expertise of its employees, the Group leverages an industrial, managerial and societal model that is virtuous and value-accretive. As a contributive corporate citizen, Eramet strives for a sustainable and responsible industry.
Eramet employs around 13,000 people in 20 countries with sales of approximately â¬4 billion in 2018.
For further information, go to www.eramet.com
| INVESTOR CONTACT Executive VP Strategy and Innovation - Investor Relations Philippe Gundermann T. +33 1 45 38 42 78 Investor Relations Manager Sandrine Nourry-Dabi T. +33 1 45 38 37 02  Follow us with the Eramet Finance app: IOS: https://itunes.apple.com/fr/app/eramet-finance/id1115212055?mt=8 Android: https://play.google.com/store/apps/details?id=com.eramet.finance  | PRESS CONTACT Communications Director Pauline Briand T. +33 1 45 38 31 76 pauline.briand@eramet.com  Image 7 Marie Artzner T. +33 1 53 70 74 31 | M. +33 6 75 74 31 73 martzner@image7.fr  |
Attachment
EVS Broadcast Equipment reports update of share buyback program
Publication on December 09, 2019, 5.45pm CET
Regulated information â reporting share buyback
EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR)
EVS reports update of share buyback program
EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on October 24, 2018, took place between December 02, 2019 and December 06, 2019.
| Date | Number of shares acquired | Average price (EUR) | Total (EUR) |
| 02/12/2019 | 500 | 20.5750 | 10,288 |
| 03/12/2019 | 1500 | 20.4333 | 30,650 |
| 04/12/2019 | 1000 | 20.5000 | 20,500 |
| 05/12/2019 | 1000 | 20.5750 | 20,575 |
| 06/12/2019 | 395 | 20.7133 | 8,182 |
As of December 06, 2019, and since the start of the buyback program, EVS has bought 315,731 shares at an average price of EURÂ 20,9793, representing in total EUR 6,623,808.
After aforementioned transactions the total number of own shares amounts now to 394,379 shares as of December 06, 2019 (including 93,144 shares already held by the company before the start of the share buyback program and taking into account the 14,496 shares distributed as part of the employees profit sharing plan as approved by the May 2019 OGM ) .
This information is also available here https://evs.com/en/corporate/investor-relations/stock-info/share-buyback.
About EVS
EVS is globally recognized as the leader in live video technology for broadcast and new media productions. Our passion and purpose are to help our clients craft immersive stories that trigger the best return on emotion. Through a wide range of products and solutions, we deliver the most gripping live sports images, buzzing entertainment shows and breaking news content to billions of viewers every day â and in real-time. The company is headquartered in Belgium with offices in Europe, the Middle East, Asia and North America, and provides sales and technical support to more than 100 countries. EVS is a public company traded on Euronext Brussels: EVS, ISIN: BE0003820371. For more information, please visit www.evs.com.
Contact:
Yvan ABSIL, CFO
Pierre SOLEIL, Corporate Communication & Investor Relations Manager
EVS Broadcast Equipment S.A., Liege Science Park, 13 rue du Bois Saint-Jean, B-4102 Seraing, Belgium
Tel : +32 4 361 70 13. E-mail : corpcom@evs.com; www.evs.com
Â
Attachment
BONDUELLE - Monthly statement of the number of shares and voting rights
BONDUELLE
A French SCA (Partnership Limited by Shares) with a capital of 56 942 095 Euros
Head Office: La Woestyne 59173 Renescure, France
Registered under number: 447 250 044 (Dunkerque Commercial and Companies Register)
MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS
AND SHARES FORMING THE COMPANYâS SHARE CAPITAL
ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FINANCIAL MARKET AUTHORITY
| Date of latest information | Total number of shares forming the capital | Number of voting rights |
| Â Â 30.11.2019 | Â Â 32 538 340 | Â Theoretical Total 51 159 239 |
| Â | Â | Â Actual Total * 50 726 060 Â |
| *Actual Total  = | total number of voting rights attached to the total number of shares |
|  | â shares without voting rights    |
Attachment
